您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > ICA-121431
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
ICA-121431
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
ICA-121431图片
CAS NO:313254-51-2
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW) 449.54
Formula C23H19N3O3S2
CAS No. 313254-51-2
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: ≥ 40 mg/mL
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo) O=C(NC1=CC=C(S(=O)(NC2=NC=CS2)=O)C=C1)C(C3=CC=CC=C3)C4=CC=CC=C4
Synonyms ICA-121431; ICA 121431; ICA121431.
实验参考方法
In Vitro

In vitro activity: ICA-121431 is a potent, highly selective small molecule inhibitor of the human Nav1.3 and Nav1.1 voltage gated sodium channels with IC50 of 19 nM. It exhibit up to 1,000-fold selectivity for human Nav1.3/Nav1.1 (ICA-121431, IC50, 19 nM) vs. other TTX-sensitive or resistant (i.e., Nav1.5) sodium channels, in other words, it has little or no activity against human Nav1.5 or Nav1.7 channels. Voltage-gated sodium channels initiate action potentials in brain neurons, and sodium channel blockers are used in therapy of epilepsy.


Kinase Assay: ICA-121431 is a potent, highly selective small molecule inhibitor of the human Nav1.3 and Nav1.1 voltage gated sodium channels with IC50 of 19 nM. It exhibit up to 1,000-fold selectivity for human Nav1.3/Nav1.1 (ICA-121431, IC50, 19 nM) vs. other TTX-sensitive or resistant (i.e., Nav1.5) sodium channels


Cell Assay: Coverslips containing HEK-293 cells expressing unmodified and mutated Navchannels were placed in a recording chamber on the stage of an inverted microscope and perfused (~1 mL/min) with an extracellular solution containing 138 mM NaCl, 2 mM CaCl2, 5.4 mM KCI, 1 mM MgCl2, 10 mM glucose, and 10 mM Hepes (pH 7.4), with NaOH. Recording patch pipettes were filled with an intracellular solution containing 135 mM CsF, 5 mM NaCl, 2 mM MgCl2, 10 mM EGTA, and 10 mM Hepes (pH 7.3) with NaOH and had a resistance of 1–2 MΩ. All recordings were made at room temperature (22–24 °C) using AXOPATCH 200B amplifiers and PCLAMP software (Molecular Devices). Nav currents were measured using the whole-cell configuration of the patch clamp technique. All compounds were dissolved in DMSO to make 10-mM stock solutions, which were then diluted into extracellular solution to attain the final concentrations desired. The final concentration of DMSO (<0.3%) was found to have no significant effect on sodium currents. Test compound effects were evaluated using a protocol in which cells depolarized from a holding potential of –120 mV (or –140 mV for Nav1.5) to a membrane potential that inactivated half of the available channels for 8 s (determined empirically for each channel type) followed after a 20-ms recovery at –120 mV by a test pulse to 0 mV to assess magnitude of inhibition. Concentration response data were analyzed using nonlinear least-squares fit of the Logistic Equation (GraphPad Prism 5) to provide IC50 determinations.

In Vivo
Animal model
Formulation & Dosage
References Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):E2724-32.